MGO One Seven LLC Buys New Shares in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

MGO One Seven LLC purchased a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 17,460 shares of the company’s stock, valued at approximately $269,000. MGO One Seven LLC owned 0.06% of ClearPoint Neuro at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in CLPT. Invesco Ltd. bought a new position in ClearPoint Neuro during the fourth quarter worth $3,814,000. Barclays PLC raised its holdings in ClearPoint Neuro by 1,070.9% during the fourth quarter. Barclays PLC now owns 66,436 shares of the company’s stock worth $1,022,000 after buying an additional 60,762 shares during the last quarter. Bradley Foster & Sargent Inc. CT bought a new position in shares of ClearPoint Neuro in the fourth quarter valued at $871,000. Virtu Financial LLC acquired a new position in shares of ClearPoint Neuro during the fourth quarter valued at about $316,000. Finally, Conway Capital Management Inc. increased its position in shares of ClearPoint Neuro by 13.9% during the fourth quarter. Conway Capital Management Inc. now owns 161,225 shares of the company’s stock worth $2,480,000 after acquiring an additional 19,725 shares in the last quarter. 30.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on CLPT. Stifel Nicolaus lifted their target price on ClearPoint Neuro from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st. Lake Street Capital lifted their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st. Finally, B. Riley upped their target price on ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, January 28th.

ClearPoint Neuro Stock Down 0.3 %

CLPT opened at $14.67 on Wednesday. ClearPoint Neuro, Inc. has a twelve month low of $5.11 and a twelve month high of $19.22. The company’s 50-day moving average price is $13.07 and its two-hundred day moving average price is $14.14. The stock has a market cap of $410.47 million, a price-to-earnings ratio of -21.26 and a beta of 0.97.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $7.77 million for the quarter, compared to the consensus estimate of $8.23 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. As a group, sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.